MCID: PNC035
MIFTS: 79

Pancreatic Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 57 38 12 76 53 75 37 13 13 13 55 43 15
Pancreatic Carcinoma 57 12 53 75 55 44 15 73
Pancreatic Carcinoma, Familial 12 76 73
Familial Pancreatic Carcinoma 53 59 29
Carcinoma of Pancreas 12 29 6
Pancreatic Acinar Carcinoma 57 75
Familial Pancreatic Cancer 53 59
Pancreatic Neoplasm 12 73
Pancreatic Tumor 12 55
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Pancreatic Cancer, Susceptibility to 6
Hereditary Pancreatic Carcinoma 53
Malignant Neoplasm of Pancreas 73
Pancreatic Carcinoma, Somatic 57
Hereditary Pancreatic Cancer 53
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 57
Neoplasm of the Pancreas 29
Cancer of the Pancreas 53
Pancreatic Neoplasms 44
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 53
Cancer, Pancreatic 40
Pancreas Neoplasm 12
Exocrine Cancer 12
Pancreas Cancer 53
Pnca 75

Characteristics:

Orphanet epidemiological data:

59
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

32
pancreatic cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Pancreatic Cancer

NIH Rare Diseases : 53 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing. Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include:BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant; in some cases, is may be multifactorial. It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection, chemotherapy, and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis.

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to pancreas adenocarcinoma and breast cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and DNA Damage Response. The drugs Afinitor and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, the pancreas and pancreas, and related phenotypes are pancreatic adenocarcinoma and exocrine pancreatic insufficiency

OMIM : 57 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

UniProtKB/Swiss-Prot : 75 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MedlinePlus : 43 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

Wikipedia : 76 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 pancreas adenocarcinoma 34.0 KRAS SMAD4 TP53
2 breast cancer 32.6 BRCA1 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR155
3 adenocarcinoma 32.5 KRAS SMAD4 STK11 TP53
4 gastric cancer 32.4 CDKN2B-AS1 HOTTIP KRAS LINC00673 MALAT1 MIR21
5 melanoma 32.4 CDKN2B-AS1 LINC00673 MALAT1 MIR15A MIR221 MIR34A
6 pancreatic ductal adenocarcinoma 32.3 HOTTIP LINC00673 MALAT1 MIR155 MIR21 MIR221
7 colorectal cancer 32.3 BRCA1 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR10A
8 ovarian cancer 32.2 BRCA1 CDKN2B-AS1 KRAS MALAT1 MIR155 MIR15A
9 cholangiocarcinoma 32.1 KRAS MALAT1 MIR21 SMAD4 TP53
10 peutz-jeghers syndrome 32.0 SMAD4 STK11 TP53
11 lung cancer 32.0 CDKN2B-AS1 HOTTIP KRAS LINC00673 MALAT1 MIR155
12 small cell cancer of the lung 31.9 HOTTIP MALAT1 MIR21 TP53
13 glioma 31.9 CDKN2B-AS1 HOTTIP MALAT1 MIR15A MIR21 MIR221
14 prostate cancer 31.8 BRCA1 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR10A
15 lung cancer susceptibility 3 31.7 KRAS MALAT1 SMAD4 STK11 TP53
16 glioblastoma 31.7 MALAT1 MIR21 MIR221 MIR34A TP53
17 myeloma, multiple 31.6 KRAS MALAT1 MIR15A PVT1 TP53
18 retinoblastoma 31.6 MALAT1 MIR34A MIR34B TP53
19 dermatomyositis 31.4 MIR21 MIR221 MIR34A
20 glioblastoma multiforme 31.3 MIR155 MIR21 MIR221 TP53
21 polymyositis 31.3 MIR155 MIR21
22 melanoma-pancreatic cancer syndrome 12.4
23 pancreatic cancer 4 12.3
24 pancreatic cancer 1 12.2
25 pancreatic cancer 3 12.2
26 pancreatic cancer 2 12.2
27 osteoclast-like giant cell neoplasm of the pancreas 12.1
28 adenosquamous pancreas carcinoma 12.0
29 pancreatic cancer, childhood 11.9
30 esophageal cancer 11.8 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR21 MIR34A
31 adamantinoma of long bones 11.8 BRCA1 CDKN2B-AS1 HOTTIP KRAS MALAT1 PVT1
32 hepatocellular carcinoma 11.7 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR155 MIR15A
33 squamous cell carcinoma 11.7 CDKN2B-AS1 KRAS MALAT1 SMAD4 STK11 TP53
34 cervical cancer 11.7 CDKN2B-AS1 MALAT1 MIR21 PVT1 SMAD4 STK11
35 bladder cancer 11.7 CDKN2B-AS1 KRAS MALAT1 MIR10A MIR21 MIR221
36 gastrointestinal system cancer 11.7 KRAS MALAT1 SMAD4 TP53
37 mutyh-associated polyposis 11.7 KRAS SMAD4 TP53
38 gallbladder cancer 11.6 CDKN2B-AS1 KRAS MALAT1 TP53
39 cowden disease 11.6 BRCA1 MIR21 SMAD4 STK11
40 leukemia, acute myeloid 11.6 CDKN2B-AS1 KRAS MALAT1 MIR155 MIR21 MIR221
41 osteogenic sarcoma 11.6 CDKN2B-AS1 HOTTIP MALAT1 PVT1 TP53
42 biliary tract neoplasm 11.6 KRAS SMAD4 TP53
43 respiratory system cancer 11.6 KRAS MALAT1 STK11 TP53
44 esophagus adenocarcinoma 11.6 MIR21 SMAD4 TP53
45 dysplastic nevus syndrome 11.6
46 ovarian cancer 1 11.6 BRCA1 KRAS TP53
47 tongue squamous cell carcinoma 11.6 HOTTIP LINC00673 MALAT1 MIR21 TP53
48 malignant ovarian surface epithelial-stromal neoplasm 11.6 BRCA1 KRAS TP53
49 leukemia, chronic lymphocytic 11.6 KRAS MIR155 MIR15A MIR21 MIR221 MIR34A
50 ovary epithelial cancer 11.6 BRCA1 KRAS TP53

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Biliary Tract Neoplasm
Cholangitis Cholestasis
Deficiency Anemia Intestinal Obstruction
Pancreatic Agenesis 1 Pancreatitis, Hereditary
Protein-Energy Malnutrition Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Symptoms via clinical synopsis from OMIM:

57
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma


Clinical features from OMIM:

260350

Human phenotypes related to Pancreatic Cancer:

59 32 (show all 26)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pancreatic adenocarcinoma 59 32 obligate (100%) Obligate (100%) HP:0006725
2 exocrine pancreatic insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0001738
3 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
4 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
5 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
6 back pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0003418
7 poor appetite 59 32 hallmark (90%) Very frequent (99-80%) HP:0004396
8 chronic fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012432
9 jaundice 59 32 frequent (33%) Frequent (79-30%) HP:0000952
10 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
11 intestinal pseudo-obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0004389
12 functional intestinal obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0005249
13 extrahepatic cholestasis 59 32 frequent (33%) Frequent (79-30%) HP:0012334
14 diabetes mellitus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000819
15 hepatosplenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001433
16 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
17 intermittent diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002254
18 melanoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002861
19 neoplasm of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0002896
20 elevated hepatic transaminases 59 32 occasional (7.5%) Occasional (29-5%) HP:0002910
21 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
22 colon cancer 59 32 occasional (7.5%) Occasional (29-5%) HP:0003003
23 ovarian carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0025318
24 peritoneal abscess 59 32 occasional (7.5%) Occasional (29-5%) HP:0100592
25 neoplasm of the pancreas 32 HP:0002894
26 increased level of l-fucose in urine 32 HP:0410067

UMLS symptoms related to Pancreatic Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas, pruritus

Drugs & Therapeutics for Pancreatic Cancer

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
SecreFlo 18 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
5
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
6
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 665)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53608-75-6
2
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
3
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
5
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
6
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
11
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
12
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
13
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
14
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
15
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
16
Iron Approved Phase 4,Phase 2 7439-89-6 23925
17
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
18
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
20
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
21
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
22
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
23
Etomidate Approved Phase 4 33125-97-2 36339 667484
24
Meperidine Approved Phase 4 57-42-1 4058
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
28
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
29
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
30
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
31
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754
32
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 23994
33
Desflurane Approved Phase 4 57041-67-5 42113
34
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
35
Thrombin Approved, Investigational Phase 4
36
Tegafur Approved, Investigational Phase 4,Phase 2,Phase 1 17902-23-7 5386
37
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
38
Butyric Acid Experimental, Investigational Phase 4,Phase 1,Phase 2 107-92-6 264
39 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Hematinics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
49 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2330)
# Name Status NCT ID Phase Drugs
1 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
3 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
4 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
5 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
6 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
7 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
8 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
9 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Completed NCT02238847 Phase 4
10 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
11 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
12 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
13 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
14 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
15 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
16 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
17 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
18 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
19 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
20 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
21 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
22 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
23 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
24 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
25 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
26 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
27 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
28 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
29 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
30 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
31 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4 Hydrocortisone;Pasireotide
32 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
33 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
34 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
35 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
36 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
37 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
38 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
39 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
40 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
41 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
42 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
43 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
44 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
45 Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Unknown status NCT01836432 Phase 3 FOLFIRINOX;Gemcitabine;Capecitabine;Nab-Paclitaxel
46 A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients Unknown status NCT02854072 Phase 3 GV1001;Gemcitabine;Capecitabine
47 Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain Unknown status NCT02510066 Phase 3
48 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
49 A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer Unknown status NCT00789633 Phase 3 masitinib (AB1010);placebo
50 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29 KRAS SMAD4 STK11 TP53
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29

Anatomical Context for Pancreatic Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

19
The Pancreas

MalaCards organs/tissues related to Pancreatic Cancer:

41
Pancreas, Liver, Lung, Testes, T Cells, Colon, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 5978)
# Title Authors Year
1
Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells. ( 29978609 )
2018
2
IL-35 hinders endogenous anti-tumor T cell immunity and responsiveness to immunotherapy in pancreatic cancer. ( 29980536 )
2018
3
MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. ( 29978477 )
2018
4
Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. ( 29451897 )
2018
5
Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. ( 29761833 )
2018
6
3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. ( 29805624 )
2018
7
Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. ( 29442211 )
2018
8
A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. ( 29451172 )
2018
9
Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. ( 29975353 )
2018
10
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3I^/Snail signaling. ( 29980787 )
2018
11
What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. ( 29971463 )
2018
12
LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. ( 29269518 )
2018
13
Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. ( 27742762 )
2018
14
Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-cohort Study in Denmark. ( 29432727 )
2018
15
Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. ( 29061505 )
2018
16
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
17
Focal Autoimmune Pancreatitis Mimicking Pancreatic Cancer on FDG PET/CT Imaging. ( 29189377 )
2018
18
Treatment of pancreatic cancer with intravenous vitamin C: a case report. ( 29438178 )
2018
19
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer. ( 29366960 )
2018
20
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. ( 29435178 )
2018
21
Stemness and anti-cancer drug resistance in ABCG2 highly expressed pancreatic cancer is induced on 3D-culture condition. ( 29444383 )
2018
22
Activation of PPARI+ by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/I^-catenin pathway. ( 29059162 )
2018
23
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. ( 29287624 )
2018
24
Deficiencies in Natural Killer Cell Numbers, Expansion, and Function at the Pre-Neoplastic Stage of Pancreatic Cancer by KRAS Mutation in the Pancreas of Obese Mice. ( 29977235 )
2018
25
Multicenter study of early pancreatic cancer in Japan. ( 29170051 )
2018
26
LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition. ( 29667486 )
2018
27
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( 28895032 )
2018
28
Combination Effects of Hispidin and Gemcitabine <i>via</i> Inhibition of Stemness in Pancreatic Cancer Stem Cells. ( 29970519 )
2018
29
MicroRNA-221-3p is up-regulated and serves as a potential biomarker in pancreatic cancer. ( 28434388 )
2018
30
The application of a three-dimensional visualized seed planning and navigation system in<sup>125</sup>I seed implantation for pancreatic cancer. ( 29440912 )
2018
31
CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. ( 29286153 )
2018
32
PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer. ( 29128633 )
2018
33
POINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer. ( 29447420 )
2018
34
TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate-induced growth inhibition in pancreatic cancer cells. ( 29435064 )
2018
35
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. ( 29441441 )
2018
36
Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. ( 29978472 )
2018
37
Localized autoimmune pancreatitis mimicking pancreatic cancer: Case report and literature review. ( 29332510 )
2018
38
TOP2A induces malignant character of pancreatic cancer through activating I^-catenin signaling pathway. ( 29045811 )
2018
39
I^2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. ( 29249692 )
2018
40
Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. ( 28913878 )
2018
41
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. ( 29599309 )
2018
42
Assessment of folate receptor alpha and beta expression in selection of lung and pancreatic cancer patients for receptor targeted therapies. ( 29435118 )
2018
43
FOXC1 plays a crucial role in the growth of pancreatic cancer. ( 29976975 )
2018
44
Contrast-Enhanced Endoscopic Ultrasound for Differentially Diagnosing Autoimmune Pancreatitis and Pancreatic Cancer. ( 29699060 )
2018
45
Significance of combined preoperative serum Alb and dNLR for diagnosis of pancreatic cancer. ( 29338337 )
2018
46
A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. ( 29438371 )
2018
47
Investigation into metastatic processes and the therapeutic effects of gemcitabine on human pancreatic cancer using an orthotopic SUIT-2 pancreatic cancer mouse model. ( 29435042 )
2018
48
SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. ( 29059173 )
2018
49
Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1I^ from activated macrophages leads to poor prognosis in pancreatic cancer. ( 29224225 )
2018
50
Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. ( 29445028 )
2018

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6
(show top 50) (show all 172)
# Gene Variation Type Significance SNP ID Assembly Location
1 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 GRCh37 Chromosome 19, 1207020: 1207020
2 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 GRCh38 Chromosome 19, 1207021: 1207021
3 STK11 NM_000455.4(STK11): c.650delC (p.Pro217Argfs) deletion Pathogenic rs397518442 GRCh37 Chromosome 19, 1220632: 1220632
4 STK11 NM_000455.4(STK11): c.650delC (p.Pro217Argfs) deletion Pathogenic rs397518442 GRCh38 Chromosome 19, 1220633: 1220633
5 STK11 NM_000455.4(STK11): c.936delA (p.Lys312Asnfs) deletion Pathogenic rs397518443 GRCh37 Chromosome 19, 1222999: 1222999
6 STK11 NM_000455.4(STK11): c.936delA (p.Lys312Asnfs) deletion Pathogenic rs397518443 GRCh38 Chromosome 19, 1223000: 1223000
7 ACVR1B NM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs) deletion Pathogenic rs387906389 GRCh37 Chromosome 12, 52380624: 52380628
8 ACVR1B NM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs) deletion Pathogenic rs387906389 GRCh38 Chromosome 12, 51986840: 51986844
9 ACVR1B NM_020328.3(ACVR1B): c.1385-502_1515+24del deletion Pathogenic GRCh37 Chromosome 12, 52385145: 52385801
10 ACVR1B NM_020328.3(ACVR1B): c.1385-502_1515+24del deletion Pathogenic GRCh38 Chromosome 12, 51991361: 51992017
11 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 GRCh37 Chromosome 18, 48591909: 48591909
12 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 GRCh38 Chromosome 18, 51065539: 51065539
13 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 GRCh37 Chromosome 18, 48604655: 48604655
14 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 GRCh38 Chromosome 18, 51078285: 51078285
15 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 GRCh37 Chromosome 18, 48604721: 48604721
16 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 GRCh38 Chromosome 18, 51078351: 51078351
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 GRCh37 Chromosome 17, 7579582: 7579582
20 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 GRCh38 Chromosome 17, 7676264: 7676264
21 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
22 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
23 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
24 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
25 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
26 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh38 Chromosome 17, 43057065: 43057065
27 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 GRCh37 Chromosome 18, 48593485: 48593485
28 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 GRCh38 Chromosome 18, 51067115: 51067115
29 PALLD NM_016081.3(PALLD): c.-83+8A> G single nucleotide variant Benign/Likely benign rs143268375 GRCh38 Chromosome 4, 168497202: 168497202
30 PALLD NM_016081.3(PALLD): c.-83+8A> G single nucleotide variant Benign/Likely benign rs143268375 GRCh37 Chromosome 4, 169418353: 169418353
31 PALLD NM_016081.3(PALLD): c.3205C> T (p.Leu1069=) single nucleotide variant Benign/Likely benign rs59633770 GRCh38 Chromosome 4, 168924976: 168924976
32 PALLD NM_016081.3(PALLD): c.3205C> T (p.Leu1069=) single nucleotide variant Benign/Likely benign rs59633770 GRCh37 Chromosome 4, 169846127: 169846127
33 SMAD4 NM_005359.5(SMAD4): c.677C> T (p.Ala226Val) single nucleotide variant Conflicting interpretations of pathogenicity rs539739051 GRCh38 Chromosome 18, 51058134: 51058134
34 SMAD4 NM_005359.5(SMAD4): c.677C> T (p.Ala226Val) single nucleotide variant Conflicting interpretations of pathogenicity rs539739051 GRCh37 Chromosome 18, 48584504: 48584504
35 STK11 NM_000455.4(STK11): c.582C> A (p.Asp194Glu) single nucleotide variant Likely pathogenic rs786202134 GRCh37 Chromosome 19, 1220489: 1220489
36 STK11 NM_000455.4(STK11): c.582C> A (p.Asp194Glu) single nucleotide variant Likely pathogenic rs786202134 GRCh38 Chromosome 19, 1220490: 1220490
37 PALLD NM_001166110.1(PALLD): c.1272T> C (p.Pro424=) single nucleotide variant Benign/Likely benign rs114250766 GRCh37 Chromosome 4, 169837112: 169837112
38 PALLD NM_001166110.1(PALLD): c.1272T> C (p.Pro424=) single nucleotide variant Benign/Likely benign rs114250766 GRCh38 Chromosome 4, 168915961: 168915961
39 PALLD NM_001166110.1(PALLD): c.1847-4G> A single nucleotide variant Likely benign rs113515140 GRCh38 Chromosome 4, 168926209: 168926209
40 PALLD NM_001166110.1(PALLD): c.1847-4G> A single nucleotide variant Likely benign rs113515140 GRCh37 Chromosome 4, 169847360: 169847360
41 PALLD NM_001166108.1(PALLD): c.-178G> A single nucleotide variant Uncertain significance rs886059207 GRCh37 Chromosome 4, 169418250: 169418250
42 PALLD NM_001166108.1(PALLD): c.-178G> A single nucleotide variant Uncertain significance rs886059207 GRCh38 Chromosome 4, 168497099: 168497099
43 PALLD NM_001166108.1(PALLD): c.-161A> T single nucleotide variant Benign rs2710836 GRCh37 Chromosome 4, 169418267: 169418267
44 PALLD NM_001166108.1(PALLD): c.-161A> T single nucleotide variant Benign rs2710836 GRCh38 Chromosome 4, 168497116: 168497116
45 PALLD NM_001166108.1(PALLD): c.-139G> T single nucleotide variant Uncertain significance rs886059208 GRCh37 Chromosome 4, 169418289: 169418289
46 PALLD NM_001166108.1(PALLD): c.-139G> T single nucleotide variant Uncertain significance rs886059208 GRCh38 Chromosome 4, 168497138: 168497138
47 PALLD NM_001166108.1(PALLD): c.-8G> A single nucleotide variant Likely benign rs372273201 GRCh37 Chromosome 4, 169432648: 169432648
48 PALLD NM_001166108.1(PALLD): c.-8G> A single nucleotide variant Likely benign rs372273201 GRCh38 Chromosome 4, 168511497: 168511497
49 PALLD NM_001166108.1(PALLD): c.18C> T (p.Ser6=) single nucleotide variant Benign rs61051061 GRCh37 Chromosome 4, 169432673: 169432673
50 PALLD NM_001166108.1(PALLD): c.18C> T (p.Ser6=) single nucleotide variant Benign rs61051061 GRCh38 Chromosome 4, 168511522: 168511522

Cosmic variations for Pancreatic Cancer:

9
(show top 50) (show all 80)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6920561 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 30
2 COSM6955726 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 30
3 COSM6977589 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 30
4 COSM6977592 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 30
5 COSM4754647 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 30
6 COSM6784678 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 30
7 COSM14249 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 30
8 COSM6955723 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.2816C>A p.S939* 3:47120311-47120311 30
9 COSM6977590 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 30
10 COSM6977587 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 30
11 COSM6934092 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 30
12 COSM6974631 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 30
13 COSM6941250 PTPRD pancreas,NS,carcinoma,acinar carcinoma c.5594G>C p.R1865T 9:8319907-8319907 30
14 COSM5327 PTEN pancreas,NS,carcinoma,acinar carcinoma c.740T>A p.L247* 10:87957958-87957958 30
15 COSM6955728 PTEN pancreas,NS,carcinoma,acinar carcinoma c.686C>A p.S229* 10:87957904-87957904 30
16 COSM6927948 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.3622G>A p.E1208K 16:81956746-81956746 30
17 COSM6955738 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.2462C>A p.S821Y 16:81927126-81927126 30
18 COSM763 PIK3CA pancreas,NS,carcinoma,acinar carcinoma c.1633G>A p.E545K 3:179218303-179218303 30
19 COSM4186192 PBRM1 pancreas,NS,carcinoma,acinar carcinoma c.2884G>T p.D962Y 3:52589151-52589151 30
20 COSM6955743 PAK5 pancreas,NS,carcinoma,acinar carcinoma c.1657C>A p.L553M 20:9557694-9557694 30
21 COSM6961498 NKX2-1 pancreas,NS,carcinoma,acinar carcinoma c.578A>T p.H193L 14:36517816-36517816 30
22 COSM6976390 NFE2L2 pancreas,NS,carcinoma,acinar carcinoma c.838G>T p.D280Y 2:177231765-177231765 30
23 COSM6977500 NF1 pancreas,NS,carcinoma,acinar carcinoma c.7786G>T p.V2596F 17:31357007-31357007 30
24 COSM532 KRAS pancreas,NS,carcinoma,acinar carcinoma c.38G>A p.G13D 12:25245347-25245347 30
25 COSM520 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>T p.G12V 12:25245350-25245350 30
26 COSM521 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>A p.G12D 12:25245350-25245350 30
27 COSM221052 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.9187C>T p.Q3063* 12:49037359-49037359 30
28 COSM6936263 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.10090C>T p.Q3364* 12:49033805-49033805 30
29 COSM6921306 INPP4B pancreas,NS,carcinoma,acinar carcinoma c.292T>G p.F98V 4:142403018-142403018 30
30 COSM6955721 IKBKE pancreas,NS,carcinoma,acinar carcinoma c.1956G>T p.Q652H 1:206493289-206493289 30
31 COSM28747 IDH1 pancreas,NS,carcinoma,acinar carcinoma c.394C>T p.R132C 2:208248389-208248389 30
32 COSM3430388 HIST1H3B pancreas,NS,carcinoma,acinar carcinoma c.258G>C p.Q86H 6:26031803-26031803 30
33 COSM6934091 GRIN2A pancreas,NS,carcinoma,acinar carcinoma c.527T>A p.I176N 16:9938439-9938439 30
34 COSM27895 GNAS pancreas,NS,carcinoma,acinar carcinoma c.602G>A p.R201H 20:58909366-58909366 30
35 COSM6955729 FGF19 pancreas,NS,carcinoma,acinar carcinoma c.574C>A p.L192M 11:69699339-69699339 30
36 COSM4967292 FAT1 pancreas,NS,carcinoma,acinar carcinoma c.11216C>T p.A3739V 4:186603310-186603310 30
37 COSM6934088 EGFR pancreas,NS,carcinoma,acinar carcinoma c.3541G>C p.A1181P 7:55205525-55205525 30
38 COSM6960278 EED pancreas,NS,carcinoma,acinar carcinoma c.445A>T p.T149S 11:86256405-86256405 30
39 COSM5689 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>G p.S45C 3:41224646-41224646 30
40 COSM5676 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.122C>T p.T41I 3:41224634-41224634 30
41 COSM5667 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>T p.S45F 3:41224646-41224646 30
42 COSM5679 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.110C>G p.S37C 3:41224622-41224622 30
43 COSM5686 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.100G>A p.G34R 3:41224612-41224612 30
44 COSM6955735 CD276 pancreas,NS,carcinoma,acinar carcinoma c.308G>T p.G103V 15:73702483-73702483 30
45 COSM6955741 AXIN2 pancreas,NS,carcinoma,acinar carcinoma c.1665C>A p.C555* 17:65537371-65537371 30
46 COSM6955736 AXIN1 pancreas,NS,carcinoma,acinar carcinoma c.1210G>T p.E404* 16:304348-304348 30
47 COSM6977595 ATRX pancreas,NS,carcinoma,acinar carcinoma c.5438G>A p.G1813E 23:77618816-77618816 30
48 COSM6955731 ATM pancreas,NS,carcinoma,acinar carcinoma c.6415G>T p.E2139* 11:108320021-108320021 30
49 COSM19021 APC pancreas,NS,carcinoma,acinar carcinoma c.4330C>T p.Q1444* 5:112839924-112839924 30
50 COSM94388 pancreas,NS,carcinoma,acinar carcinoma c.2531G>A p.R844H 20:58909366-58909366 30

Copy number variations for Pancreatic Cancer from CNVD:

7 (show top 50) (show all 15981)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss HIAT1 Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCD1 Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss EDG1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss APITD1 Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss HRMT1L6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5 Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss FAM102B Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss KIAA1324 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Pancreatic cancer hsa05212

GO Terms for Pancreatic Cancer

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.93 MIR15A MIR21 MIR221 SMAD4 STK11 TP53
2 positive regulation of gene expression GO:0010628 9.88 ACVR1B BRCA1 KRAS MIR155 MIR21 TP53
3 negative regulation of cell growth GO:0030308 9.83 ACVR1B SMAD4 STK11 TP53
4 negative regulation of angiogenesis GO:0016525 9.8 MIR10A MIR15A MIR21 MIR34A
5 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.78 MIR21 MIR221 SMAD4
6 negative regulation of protein kinase B signaling GO:0051898 9.77 MIR34A MIR34B MIR34C
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.74 MIR21 MIR221 SMAD4
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.73 MIR155 MIR15A MIR221
9 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.69 MIR15A MIR34A MIR96
10 positive regulation of cell cycle arrest GO:0071158 9.65 BRCA1 MIR34A TP53
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.63 BRCA1 TP53
12 positive regulation of histone H3-K4 methylation GO:0051571 9.62 BRCA1 SMAD4
13 negative regulation of cardiac muscle hypertrophy GO:0010614 9.62 MIR21 SMAD4
14 miRNA mediated inhibition of translation GO:0035278 9.62 MIR15A MIR21 MIR221 MIR96
15 regulation of protein kinase B signaling GO:0051896 9.61 MIR21 STK11
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.61 MIR15A MIR21 MIR34A
17 positive regulation of histone H3-K9 acetylation GO:2000617 9.6 BRCA1 SMAD4
18 negative regulation of regulatory T cell differentiation GO:0045590 9.58 MIR155 MIR21
19 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR155 MIR221
20 negative regulation of cell adhesion molecule production GO:0060354 9.55 MIR155 MIR221
21 negative regulation of vascular wound healing GO:0061044 9.54 MIR155 MIR34A
22 positive regulation of cellular senescence GO:2000774 9.54 KRAS MIR10A MIR34A
23 negative regulation of sprouting angiogenesis GO:1903671 9.46 MIR221 MIR34A MIR34B MIR34C
24 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.43 MIR155 MIR34B MIR34C
25 positive regulation of connective tissue replacement GO:1905205 9.26 MIR155 MIR34A MIR34B MIR34C
26 gene silencing by miRNA GO:0035195 9.17 MIR10A MIR155 MIR15A MIR21 MIR221 MIR34A

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR10A MIR155 MIR15A MIR21 MIR221 MIR34A
2 LRR domain binding GO:0030275 8.96 KRAS STK11

Sources for Pancreatic Cancer

3 CDC
7